<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210524051384N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-10-18</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Oxandrolone and propranolole in burn patients</public_title>
      <acronym>OxProp Study of Burns</acronym>
      <scientific_title>Assessing the effects of Oxandrolone and Propranolole administration on improving post-burn hyper-metabolic changes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>768</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56776</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: For randomization, in each group, we will have randomization separately:
In pediatric group: For randomization of treatment between groups, a randomized permutation block (4) method will be used. Considering the time of the sample's entry into the study and drug labeling (A and B, considering that the double-blind study is the only statistical analyzer informed of the type of allocated treatment) 
In adult group: For randomization of treatment between groups, permutation randomization block with size 4 will be used. Considering the time of the sample's entry into the study and drug labeling (A and B, considering that the double-blind study is the only statistical analyzer informed of the type of allocated treatment) 
In the elderly group: For randomization of treatment between groups, a randomized permutation block (4) method will be used. Considering the time of the entry of individuals into the study and drug labeling (A and B, considering that the double-blind study is the only statistical analyzer informed of the type of allocated treatment), Blinding description: For blinding, the drug manufacturer (AbuReihan Pharmaceutical Company) is requested to produce the drug and placebo in the same form and to distinguish between them only with labels A and B. Explain that each of the two types of drugs A and B are related to the desired treatment or placebo in a sealed envelope for researchers to send. The desired envelope will be provided to the statistics consultant. Accordingly, patients and the researcher who provides the drug to patients will be unaware of the type of drug.
Medication and placebo in similar containers and forms will be delivered to patients at the time of admission as well as in each of the patient visit blocks.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Burn Injury. Condition 2: Burn Injury.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: At the beginning of the study, burn patients referred to the Burn and Regenerative research center of Velayat, according to age, are divided into 3 groups: children 0-18, adults (19-59) and the elderly (&lt;60). Then each group in addition to receiving treatment the standard records recorded in the treatment protocols of burn patients will follow their own protocol during the study. The standard treatment for burn patients is as follows: At the time of admission, patients are admitted according to the American Burn Association (ABA) guidelines and undergo various treatments, including surgical treatment (including wound dressings, skin grafts, amniotic dressings, and other biological dressings. And supportive and non-surgical treatments (including antibiotic therapy, nutritional supplements, nutrition counseling, psychiatric counseling, physiotherapy and other rehabilitation programs). Pediatric group will enter the 7-block visits of a burn specialist.: Pediatric group in the age range of 0-18 years, with burns of 20% or more, is divided into 2 groups A (receiving medication) and group B (receiving placebo). The distribution of the drug is as follows:  Group A, candidate for receiving oxandrolone and propranolol for 1 year after the occurrence of burns, is as follows: Oxandrolone: ​​at a dose of 0.1 mg / kg, 2 times a day, orally, which is prescribed from the 5th day after the burn. (Propranolol dose is adjusted to reduce heart rate by 15%) In this visit, in addition to presenting the next visit plan, by encouraging the patient and his family and ensuring the patient's compliance in the use of drugs, the study participants are encouraged to continue the plan. The third block, on the 60th day After discharging. The patient is referred to the burn hospital of the provincial hospital and the following items are checked in him: Registration of vital signs including heart rate, respiration rate, blood pressure and body temperature, weight, BMI, Wrist / Hip ratio, triceps skinfold thickness. In this visit, in addition to presenting the next visit plan, by encouraging the patient and his family and ensuring the patient's compliance with the medication, the study participants are encouraged to continue the plan. The 4th block is at the end of the 120th day after discharge, and the cases in the previous block are checked again during the visit to the burn and regenerative research center .The 5th block is done on the 180th day after discharge. The patient is referred to the burn and regenerative research center and the opposite cases are recorded in his file: blood sample for AST, ALT, CBC, vital signs including heart rate, respiration rate, blood pressure and body temperature, weight, BMI, Wrist ratio / Hip, Triceps skinfold thickness. In this visit, in addition to presenting the next visit plan, by encouraging the patient and his family and ensuring the patient's compliance with the medication, the study participants are encouraged to continue the plan. The 6th block is done on the 270th day after discharge. The patient was referred to the burn and regenerative research center and the cases in the previous block were re-examined. Block 7, which is the last block of the visit, the patient is referred to the burn and regenerative research center and the cases in block 5 are checked and registered again. Intervention 2: Control group: Group B is a candidate for Placebo, with a shape and size quite similar to oxandrolone and propranolol. In this way, at the beginning of hospitalization (block 0), demographic information, height, weight and all information related to burns (percentage, depth, mechanism, etc.) are recorded in the relevant questionnaire. From this time until the patient is discharged from the hospital, the above information, including vital signs on a daily basis, weekly weighing, blood sampling for AST, ALT, CBC and BS on the first, third and then weekly days, wound examinations for depth , degree, infection, blood supply, discharge, color and eclipse status are recorded when changing dressings. The next block (block 1) is related to the time of discharge, when the patient is discharged with the necessary knowledge, training and recommendations, nutritional advice to continue a high-protein diet, and a 7-day visit plan. In this block, information such as number of days of hospitalization, number of days in need of respiratory support, number of days of hospitalization in ICU, number of surgical procedures, amount of skin graft used in surgery, proportion of burn area, incidence of infection, number of blood and blood products used at the time of admission (including Platelet, PC, and FFP), weight, BMI, Wrist / Hip ratio, Triceps skinfold thickness are recorded in the questionnaires. The second block is on the 30th day after discharge when the patient refers to the burn and regenerative research center and the following cases are recorded in his file: blood sample for AST, ALT, CBC, vital signs including heart rate, number respiration, blood pressure and body temperature, weight, BMI, Wrist / Hip ratio, triceps skinfold thickness. Intervention 3: Intervention group: Adults in the age group of 19 to 59 years, with burns of 20% or more, are divided into two groups A (receiving medication) and group B (receiving placebo). How to distribute the drug is as follows: Group A candidates for oxandrolone and propranolol for 4 weeks after discharge are as follows: Oxandrolone: ​​10 mg twice daily, orally, given 2-3 days after burn injury. Propranolol: At a dose of 3.3 mg / kg daily, orally, which is prescribed from day 2 after burn injury. Intervention 4: Control group: B Group B, which is a candidate for Placebo, with a shape and size quite similar to oxandrolone and propranolol. After entering the study and prescribing the drug and placebo to them, the adults enter the dual block program of the doctor's visits. At the beginning of hospitalization (block 0), demographic information, height, weight and all information related to burns (percentage, depth, mechanism, etc.) are recorded in the relevant questionnaire. From this time until the patient discharge from the hospital, the above information including vital signs on a daily basis, weekly weighing, taking blood samples to check AST, ALT, CBC and BS on the first, third and then weekly days, wound examinations in terms of depth, degree, infection, blood flow, discharge, color and condition are recorded when changing dressings. The next block (block 1) is related to the time of discharge, when the patient is discharged with the necessary knowledge, training and recommendations, nutritional advice to continue a high-protein diet, and a dual visit plan. In this block, information such as number of days of hospitalization, number of days in need of respiratory support, number of days of hospitalization in ICU, number of surgical procedures, amount of eclipse used in surgery, proportion of burn area, incidence of infection, number of blood and Blood products used at the time of admission (including Platelet, PC, and FFP), weight, and BMI are recorded in questionnaires. Block 2, which is on the 30th day after discharge, the patient is referred to the burn ward of the provincial hospital and the above items are checked in him: blood sample to check AST, ALT, CBC, recording vital signs including heart rate, respiratory rate, Blood pressure and body temperature, weight, BMI. Intervention 5: Intervention group:  Elderly group: The elderly group in the age range of 60 years and older, with burns of 20% or more, are divided into two groups A (receiving medication) and group B (receiving placebo).How to distribute the drug is as follows: Group A candidates for oxandrolone until discharge are as follows: Oxandrolone: ​​10mg, twice daily, orally, starting at the time of admission and continuing until discharge. After entering the study and prescribing the drug and placebo to him, at the beginning of hospitalization (block 0), demographic information, height, weight and all information related to burns (percentage, depth, mechanism, etc.) are recorded in the relevant questionnaire. From this time until the patient is discharged from the hospital, the above information, including vital signs on a daily basis, weekly weighing, blood sampling for AST, ALT, CBC and BS on the first, third and then weekly days, depth examinations of the wound the degree, infection, blood supply, discharge, color and condition of the eclipse are recorded when changing dressings. The next block (block 1) is related to the time of clearance. In this block, information such as number of days of hospitalization, number of days in need of respiratory support, number of days of hospitalization in ICU, number of surgical procedures, amount of eclipse used in surgery, relation to burn area, incidence of infection, number of blood and Blood products used at the time of admission (including Platelet, PC, and FFP), weight, and BMI are recorded in questionnaires.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is I haven't decided the release schedule is still unknown yet.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Haghani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Namjo St, Velayat Hospital</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193713194</zip>
        <telephone>+98 13 3336 8540</telephone>
        <email>r.haghani.r@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr.Mohammadreza Mobayen</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Namjo St, Velayat Hospital</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193713194</zip>
        <telephone>+98 13 3336 8540</telephone>
        <email>maziar.mobayen@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Sever burn injury ( TBSA&gt;20%)
aging 0 to 80 years
Negative Pregnancy test in female patients of child bearing age
Informed consent of patients entering the study</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Not treated Malignancies, known history of AIDS and complex related diseases to AIDS and HIV.
History of recent MI (Less than 6 weeks ago)
Tuberose Sclerosis, Arthritis, Cirrhosis, Hyperlipidemia, Bone or Endocrine disorders, Autoimmune Diseases
Long term consumption of corticosteroids or NSAIDS
Diabetic Mellitus Prior to burn injury
Renal failure ( Creatinine level more than 3)
Hepatic Disease ( Bilirubin level more than 3)
Anoxic Brain injury
patients suffering from asthma and history of airway constriction</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>X10</hc_code>
      <hc_code>X00-X09</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Contact with hot drinks, food, fats and cooking oils</hc_keyword>
      <hc_keyword>قرار گرفتن در معرض دود، آتش و شعله</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: At the beginning of the study, burn patients referred to the Burn and Regenerative research center of Velayat, according to age, are divided into 3 groups: children 0-18, adults (19-59) and the elderly (&lt;60). Then each group in addition to receiving treatment the standard records recorded in the treatment protocols of burn patients will follow their own protocol during the study. The standard treatment for burn patients is as follows: At the time of admission, patients are admitted according to the American Burn Association (ABA) guidelines and undergo various treatments, including surgical treatment (including wound dressings, skin grafts, amniotic dressings, and other biological dressings. And supportive and non-surgical treatments (including antibiotic therapy, nutritional supplements, nutrition counseling, psychiatric counseling, physiotherapy and other rehabilitation programs). Pediatric group will enter the 7-block visits of a burn specialist.: Pediatric group in the age range of 0-18 years, with burns of 20% or more, is divided into 2 groups A (receiving medication) and group B (receiving placebo). The distribution of the drug is as follows:  Group A, candidate for receiving oxandrolone and propranolol for 1 year after the occurrence of burns, is as follows: Oxandrolone: ​​at a dose of 0.1 mg / kg, 2 times a day, orally, which is prescribed from the 5th day after the burn. (Propranolol dose is adjusted to reduce heart rate by 15%) In this visit, in addition to presenting the next visit plan, by encouraging the patient and his family and ensuring the patient's compliance in the use of drugs, the study participants are encouraged to continue the plan. The third block, on the 60th day After discharging. The patient is referred to the burn hospital of the provincial hospital and the following items are checked in him: Registration of vital signs including heart rate, respiration rate, blood pressure and body temperature, weight, BMI, Wrist / Hip ratio, triceps skinfold thickness. In this visit, in addition to presenting the next visit plan, by encouraging the patient and his family and ensuring the patient's compliance with the medication, the study participants are encouraged to continue the plan. The 4th block is at the end of the 120th day after discharge, and the cases in the previous block are checked again during the visit to the burn and regenerative research center .The 5th block is done on the 180th day after discharge. The patient is referred to the burn and regenerative research center and the opposite cases are recorded in his file: blood sample for AST, ALT, CBC, vital signs including heart rate, respiration rate, blood pressure and body temperature, weight, BMI, Wrist ratio / Hip, Triceps skinfold thickness. In this visit, in addition to presenting the next visit plan, by encouraging the patient and his family and ensuring the patient's compliance with the medication, the study participants are encouraged to continue the plan. The 6th block is done on the 270th day after discharge. The patient was referred to the burn and regenerative research center and the cases in the previous block were re-examined. Block 7, which is the last block of the visit, the patient is referred to the burn and regenerative research center and the cases in block 5 are checked and registered again.</i_keyword>
      <i_keyword>Control group: Group B is a candidate for Placebo, with a shape and size quite similar to oxandrolone and propranolol. In this way, at the beginning of hospitalization (block 0), demographic information, height, weight and all information related to burns (percentage, depth, mechanism, etc.) are recorded in the relevant questionnaire. From this time until the patient is discharged from the hospital, the above information, including vital signs on a daily basis, weekly weighing, blood sampling for AST, ALT, CBC and BS on the first, third and then weekly days, wound examinations for depth , degree, infection, blood supply, discharge, color and eclipse status are recorded when changing dressings. The next block (block 1) is related to the time of discharge, when the patient is discharged with the necessary knowledge, training and recommendations, nutritional advice to continue a high-protein diet, and a 7-day visit plan. In this block, information such as number of days of hospitalization, number of days in need of respiratory support, number of days of hospitalization in ICU, number of surgical procedures, amount of skin graft used in surgery, proportion of burn area, incidence of infection, number of blood and blood products used at the time of admission (including Platelet, PC, and FFP), weight, BMI, Wrist / Hip ratio, Triceps skinfold thickness are recorded in the questionnaires. The second block is on the 30th day after discharge when the patient refers to the burn and regenerative research center and the following cases are recorded in his file: blood sample for AST, ALT, CBC, vital signs including heart rate, number respiration, blood pressure and body temperature, weight, BMI, Wrist / Hip ratio, triceps skinfold thickness.</i_keyword>
      <i_keyword>Intervention group: Adults in the age group of 19 to 59 years, with burns of 20% or more, are divided into two groups A (receiving medication) and group B (receiving placebo). How to distribute the drug is as follows: Group A candidates for oxandrolone and propranolol for 4 weeks after discharge are as follows: Oxandrolone: ​​10 mg twice daily, orally, given 2-3 days after burn injury. Propranolol: At a dose of 3.3 mg / kg daily, orally, which is prescribed from day 2 after burn injury.</i_keyword>
      <i_keyword>Control group: B Group B, which is a candidate for Placebo, with a shape and size quite similar to oxandrolone and propranolol. After entering the study and prescribing the drug and placebo to them, the adults enter the dual block program of the doctor's visits. At the beginning of hospitalization (block 0), demographic information, height, weight and all information related to burns (percentage, depth, mechanism, etc.) are recorded in the relevant questionnaire. From this time until the patient discharge from the hospital, the above information including vital signs on a daily basis, weekly weighing, taking blood samples to check AST, ALT, CBC and BS on the first, third and then weekly days, wound examinations in terms of depth, degree, infection, blood flow, discharge, color and condition are recorded when changing dressings. The next block (block 1) is related to the time of discharge, when the patient is discharged with the necessary knowledge, training and recommendations, nutritional advice to continue a high-protein diet, and a dual visit plan. In this block, information such as number of days of hospitalization, number of days in need of respiratory support, number of days of hospitalization in ICU, number of surgical procedures, amount of eclipse used in surgery, proportion of burn area, incidence of infection, number of blood and Blood products used at the time of admission (including Platelet, PC, and FFP), weight, and BMI are recorded in questionnaires. Block 2, which is on the 30th day after discharge, the patient is referred to the burn ward of the provincial hospital and the above items are checked in him: blood sample to check AST, ALT, CBC, recording vital signs including heart rate, respiratory rate, Blood pressure and body temperature, weight, BMI.</i_keyword>
      <i_keyword>Intervention group:  Elderly group: The elderly group in the age range of 60 years and older, with burns of 20% or more, are divided into two groups A (receiving medication) and group B (receiving placebo).How to distribute the drug is as follows: Group A candidates for oxandrolone until discharge are as follows: Oxandrolone: ​​10mg, twice daily, orally, starting at the time of admission and continuing until discharge. After entering the study and prescribing the drug and placebo to him, at the beginning of hospitalization (block 0), demographic information, height, weight and all information related to burns (percentage, depth, mechanism, etc.) are recorded in the relevant questionnaire. From this time until the patient is discharged from the hospital, the above information, including vital signs on a daily basis, weekly weighing, blood sampling for AST, ALT, CBC and BS on the first, third and then weekly days, depth examinations of the wound the degree, infection, blood supply, discharge, color and condition of the eclipse are recorded when changing dressings. The next block (block 1) is related to the time of clearance. In this block, information such as number of days of hospitalization, number of days in need of respiratory support, number of days of hospitalization in ICU, number of surgical procedures, amount of eclipse used in surgery, relation to burn area, incidence of infection, number of blood and Blood products used at the time of admission (including Platelet, PC, and FFP), weight, and BMI are recorded in questionnaires.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Metabolic State of Burn Patient. Timepoint: In children group: on admission, on discharge, and 1, 2, 4. 6. 9 and 12 months after discharge. In adults group: on admission, on discharge and 40 days after discharge. In elderly Group: On admission and on discharge. Method of measurement: Mercury sphygmomanometer, Caliper, Ruler, Scales, Laboratory tests.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Weight. Timepoint: In children group: on admission, on discharge, and 1, 2, 4. 6. 9 and 12 months after discharge. In adults group: on admission, on discharge and 40 days after discharge. In elderly Group: On admission and on discharge. Method of measurement: with scale , on kilogram.</sec_outcome>
      <sec_outcome>BMI Changes. Timepoint: In children group: on admission, on discharge, and 1, 2, 4. 6. 9 and 12 months after discharge. In adults group: on admission, on discharge and 40 days after discharge. In elderly Group: On admission and on discharge. Method of measurement: Based on weight and height.</sec_outcome>
      <sec_outcome>Wrist to hip ratio. Timepoint: In children group: on admission, on discharge, and 1, 2, 4. 6. 9 and 12 months after discharge. In adults group: on admission, on discharge and 40 days after discharge. In elderly Group: On admission and on discharge. Method of measurement: using a centimeter stick.</sec_outcome>
      <sec_outcome>Triceps Skinfold Thickness. Timepoint: In children group: on admission, on discharge, and 1, 2, 4. 6. 9 and 12 months after discharge. In adults group: on admission, on discharge and 40 days after discharge. In elderly Group: On admission and on discharge. Method of measurement: Using a Caliper.</sec_outcome>
      <sec_outcome>Hepatic transaminase. Timepoint: In children group: on admission, on discharge, and 1, 3, 6 and 12 months after discharge. In adults group: on admission, on discharge and 40 days after discharge. In elderly Group: On admission and on discharge. Method of measurement: Blood test.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-05-05</approval_date>
        <contact_name>Ethics Committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Burn and Regerenative Medicine Research Center, Poursina four-way, Namjoo Street, Rasht, Guilan. Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
